Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

Dr Reddys Laboratories (RDY) Enterprise Value (2016 - 2026)

Dr Reddys Laboratories has reported Enterprise Value over the past 10 years, most recently at -$198.0 million for Q1 2026.

  • For Q1 2026, Enterprise Value fell 40.95% year-over-year to -$198.0 million; the TTM value through Mar 2026 reached -$198.0 million, down 40.95%, while the annual FY2026 figure was -$198.0 million, 47.41% down from the prior year.
  • Enterprise Value for Q1 2026 was -$198.0 million at Dr Reddys Laboratories, down from -$140.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$87.6 million in Q1 2024 and troughed at -$751.8 million in Q1 2023.
  • A 5-year average of -$280.1 million and a median of -$198.0 million in 2026 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: tumbled 237.31% in 2023 and later surged 88.35% in 2024.
  • Year by year, Enterprise Value stood at -$222.9 million in 2022, then tumbled by 237.31% to -$751.8 million in 2023, then surged by 88.35% to -$87.6 million in 2024, then crashed by 60.3% to -$140.4 million in 2025, then tumbled by 40.95% to -$198.0 million in 2026.
  • Business Quant data shows Enterprise Value for RDY at -$198.0 million in Q1 2026, -$140.4 million in Q1 2025, and -$87.6 million in Q1 2024.